请输入货号/产品关键词 !
插入特殊字符:
  • α
  • β
  • γ
  • δ
  • ε
  • ζ
  • η
  • θ
  • κ
  • μ
  • ω
  • σ
  • τ
  • λ
  • ⅩⅢ
  • ⅩⅢ
  • ⅩⅣ
  • ⅩⅤ
  • ⅩⅦ
  • ⅩⅧ
  • 收起 ↑
热门搜索: 最新活动 文献引用 新品速递 一步法ELISA 流式抗体 铜死亡 Annexin V凋亡检测 TUNEL凋亡检测 未包被ELISA 铁死亡 双硫死亡

Recombinant Mouse CCL4 protein(His Tag)

Price: ¥5912 ¥1992

Size:
100μg 20μg
  • 表达系统: E.coli
  • 蛋白编码: P14097
  • 应用性: Cell culture
别称
4-1BB;4-1BB-;4-1BB-L;4-1BBL;AI848817;Cd137;Cd137l;Ly6;Ly63l;tumor necrosis factor (ligand) superfamily;member 9;Tnfsf9
表达系统
E.coli
序列
Ala 24-Asn 92
蛋白编码
P14097
种属
Mouse
计算分子量
8.6 kDa
表观分子量
11-17 kDa
标签
N-His
生物活性
Measure by its ability to chemoattract human PBMCs using a concentration range of 20.0 - 200.0 ng/mL. Note: Results may vary from different PBMC donors.
纯度
> 98 % as determined by reducing SDS-PAGE.
内毒素
< 0.1 EU per μg of the protein as determined by the LAL method.
保存条件
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
运输条件
This product is provided as lyophilized powder which is shipped with ice packs.
制剂
Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
复溶方法
Please refer to the printed manual for detailed information.
背景
CCL4 (C-C chemokine ligand 4), is a macrophage inflammatory protein with a chief effect in inflammation and immune-regulation, and was documented in cancer progression by promoting instability in the tumor environment. The inflammatory chemokine (C-C motif) ligand 4 (CCL4) plays an important role in the pathogenesis and progression of cancer. In particular, higher serum CCL4 levels in patients with oral squamous cell carcinoma (OSCC) are associated with a more advanced stage of disease. CCL4 may be a new molecular therapeutic target for inhibition of lymphangiogenesis and metastasis in OSCC. CCL3 and CCL4 loci may be marker SNPs for risk of HCV treatment outcome. CCL4 can enhance the recruitment of preosteoclasts to bone in the early stage, and the reduction of CCR5 promotes osteoclastogenesis when RANKL is prevalent.


微信客服 微信客服 在线留言 TOP